Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
103.33
(
-1.06%
)
Bitcoin
70,027.00
(
0.18%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 107915

Tuesday, 11/02/2010 7:28:23 PM

Tuesday, November 02, 2010 7:28:23 PM

Post# of 257262

I don't imagine MNTA would have any greater a chance of getting an injunction than Sanofi did vs MNTA.

The two cases are dissimilar. SNY sued the FDA, not another company, and the suit had nothing whatsoever to do with patents. MNTA, on the other hand, could sue Teva for infringement of its Lovenox-characterization patents. I doubt that MNTA will ever need to file such a suit, but it’s nice to have a backup plan at the ready.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now